Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

SOUTH SAN FRANCISCO, Calif., May 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the first quarter 2011. Onyx reported a non-GAAP net loss of $14.2 million, or $0.23 per diluted share, for the first quarter 2011 compared to a non-GAAP net loss of $1.5 million, or $0.02 per diluted share, for the same period in 2010. Non-GAAP net loss excludes, among other items, adjustments to contingent consideration expense in connection with Onyx's acquisition of Proteolix Inc., or Proteolix; employee stock-based compensation expense; non-cash imputed interest expense related to the application of Accounting Standards Codification ("ASC") 470-20 and charges associated with the restructuring of Onyx's development, collaboration, option and license agreement with S*BIO Pte Ltd., or S*BIO.

"2011 is a pivotal year of execution and growth for Onyx as we prepare to deliver a number of significant near-term milestones," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "The NDA for carfilzomib in relapsed and refractory multiple myeloma is on track for filing; our Phase 3 confirmatory trials, ASPIRE and FOCUS, are enrolling patients; and ONX 0912, our next generation proteasome inhibitor, is expected to advance to Phase 2. Importantly, we are ramping up our preparation for the commercialization of carfilzomib, in anticipation of a potential U.S. launch next year."

On a GAAP basis, Onyx reported a net loss of $49.2 million, or $0.78 per diluted share, for the first quarter 2011 compared to a net loss of $12.0 million, or $0.19 per diluted share, for the same period in 2010. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Loss."

Revenue from Collaboration Agreement
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013 With herbal medicines relied upon by ... U.S. Pharmacopeial Convention (USP) will provide freely available public ... ingredients used in these products. Today, USP proposes the ... Herbal Medicines Compendium ( HMC ) for ... hmc.usp.org . HMC will provide standards ...
(Date:5/19/2013)... May 20, 2013 Claret Medical, Inc. announced the ... Van Mieghem et al., Histopathology of Embolic ... of print in Circulation, May 7 th this research ... Rotterdam, the Netherlands and the pathology ... the Cardiovascular Pathology Institute, Gaithersburg, Maryland.  This ...
(Date:5/19/2013)... May 20, 2013  Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...
Breaking Medicine Technology:New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4
... 9, 2011 PDL BioPharma, Inc. (PDL) (NASDAQ: ... third quarter ended September 30, 2011. (Logo: ... third quarter of 2011 were $83.8 million, compared to $86.4 ... year-over-year decrease. Total revenues for the nine months ended September ...
... Nov. 9, 2011 Volcano Corporation (NASDAQ: ... guidance therapy tools designed to enhance the treatment of ... Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR) technologies ... patients undergoing percutaneous coronary intervention (PCI). The update was ...
Cached Medicine Technology:PDL BioPharma Announces Third Quarter 2011 Financial Results 2PDL BioPharma Announces Third Quarter 2011 Financial Results 3PDL BioPharma Announces Third Quarter 2011 Financial Results 4PDL BioPharma Announces Third Quarter 2011 Financial Results 5PDL BioPharma Announces Third Quarter 2011 Financial Results 6PDL BioPharma Announces Third Quarter 2011 Financial Results 7PDL BioPharma Announces Third Quarter 2011 Financial Results 8PDL BioPharma Announces Third Quarter 2011 Financial Results 9PDL BioPharma Announces Third Quarter 2011 Financial Results 10PDL BioPharma Announces Third Quarter 2011 Financial Results 11Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcano's Precision Guided Therapy Technologies 2Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcano's Precision Guided Therapy Technologies 3
(Date:5/20/2013)... 2013) Research presented at Digestive Disease Week (DDW) ... diarrhea (IBS-D) and hepatitis C. , An international ... In the phase II study, researchers found that the ... percent of the individuals treated. , "While there,s ... with constipation, we haven,t seen the same in IBS ...
(Date:5/20/2013)... disease (IBD) are at higher risk of melanoma, a ... Researchers found that IBD is associated with a 37 ... presented at the Digestive Disease Week 2013 conference in ... Crohn,s disease or ulcerative colitis (UC), the most common ... lining of the intestine, leading to bouts of watery ...
(Date:5/20/2013)... novel service for personalized research counseling was launched recently by ... field of providing expert research support services since a decade. ... to maintain a direct contact with mentors and get customized ... at $1000. , Students who opt for the new service ... will handle all aspects. Scholars will be assisted for choosing ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Maui’d Forever is ... and coordinator. Founded in 2003 by entrepreneur Mark Steffan, the ... and the Big Island of Hawaii. They use over 150 ... additional members to their team. , They are happy to ... Chef Kathy Morris. Kathy is an extraordinary chef and is ...
(Date:5/20/2013)... 2013 Main Virtual Office , ... with several Mathnasium franchisee's to provide live answering services ... can we answer and transfer their calls according to ... scheduling at a fraction of what they were being ... Main Virtual Office. "Core competency is critical" says ...
Breaking Medicine News(10 mins):Health News:Pharmaceutical advances offer new options for health outcomes 2Health News:Dissertation Clinic Prescribes Customized Remedy for Researchers 2Health News:Maui'd Forever Uses New Chef for Receptions and Special Private Beach Dinners 2Health News:Virtual Assistant and Mobile App Company - Main Virtual Office - Signs Up Several New Mathnasium Tutoring Centers 2
... updates the NCCN Guidelines for Non-Small Cell Lung Cancer to ... specific patients with Non-Small Cell Lung Cancer, and a revised ... National Comprehensive Cancer Network (NCCN) recently updated the ... a new section about maintenance therapy, a number of new ...
... Convention and Preconvention Program, the only medical imaging conference ... medical ultrasound, to be held March 24-27, 2010, in ... emerging applications and unique opportunities for collaboration between physicians, ... and expand into new arenas. With a ...
... the number of children diagnosed with autistic spectrum disorders over ... have found a sharp difference between the beliefs of ordinary ... incidence of autism. Expert consensus is that the rapid ... many lay people directly or indirectly affected by the disorder ...
... Group evaluated the achievements at EU level in combating ... EU cannot turn its back on CVD", expressed Dirk ... the MEP Heart Group. There is overwhelming evidence that ... It is therefore the task of decision makers at ...
... of vitamin E in the nuts, expert says , WEDNESDAY, ... reduce your risk for lung cancer and other malignancies, according ... of a type of vitamin E called gamma-tocopherol. , "It ... against certain forms of cancer. Higher intakes of gamma-tocopherol ... ...
... CORD:USE Cord Blood Bank is proud to announce that ... Department of Health and Human Services has awarded CORD:USE Cord ... supply of cord blood units for the National Cord Blood ... a prestigious designation which further validates the procedures and operations ...
Cached Medicine News:Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 2Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 3Health News:AIUM gears up for 2010 Annual Convention in San Diego, Calif. 2Health News:People affected by autism believe increase is 'real,' not diagnostic 2Health News:Want to Cut Cancer Risk? Try Munching Pistachios 2Health News:CORD:USE Cord Blood Bank Receives Grant From HRSA to Increase the National Cord Blood Inventory 2
... Preserve your data for future generations. Most ... the solid backing plate of our gel dryer, ... a frame over them to hold the cellophane ... a frame with an open area somewhat larger ...
... your data for future generations. Most gels can ... backing plate of our gel dryer, covering them ... over them to hold the cellophane flat. Tut's ... with an open area somewhat larger than the ...
... Dryer incorporates sturdy metal housing and TEFLON coated heating ... area makes it perfect for drying down large sequencing ... 40cm x 50cm (W x D) work surface ... you to optimize your heating to your gel ...
... compact air gel-drying system, Hoefers Easy Breeze can dry ... cm) or 24 Mini-Gels (8 x 10 cm) at ... an open air drying oven, a specially designed loading ... no cold trap, no awkward connections., The Gel Frame ...
Medicine Products: